PPARβ/δ agonist (GW501516) reduced inflammatory cells migration, insulin resistance and lipid levels, and increased ALT concentration in NASH experimental model321, but GW501516 has been terminated due to safety concerns. Here, GPT is linked to metabolic dysfunction-associated steatohepatitis.